Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed colorectal cancer~  * Metastatic disease~* Epidermal growth factor receptor (EGFR)-positive by immunochemistry~* Measurable or evaluable disease~* Not amenable to standard curative therapy~  * Best supportive care is the only available option~* Must have received a prior thymidylate synthase inhibitor (e.g., fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) in the adjuvant or metastatic setting~  * Combination therapy with oxaliplatin or irinotecan allowed~* Must have failed\* a prior regimen containing irinotecan and a prior regimen containing oxaliplatin for metastatic disease OR relapsed within 6 months after an adjuvant regimen containing irinotecan or oxaliplatin OR have documented unsuitability for such regimens~* No symptomatic CNS metastases NOTE: \*Failure is defined as either disease progression (clinical or radiological) or intolerance to the regimen~PATIENT CHARACTERISTICS:~Age~* 16 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* See Disease Characteristics~* Absolute granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 75,000/mm\^3~* Hemoglobin ≥ 8.0 g/dL~Hepatic~* AST and ALT ≤ 5 times upper limit of normal (ULN)~* Bilirubin ≤ 2.5 times ULN~Renal~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No uncontrolled angina~* No arrhythmias~* No cardiomyopathy~* No congestive heart failure~* No myocardial infarction\* within the past 6 months NOTE: \*Pre-treatment ECG as only evidence of infarction is allowed~Pulmonary~* No severe restrictive lung disease~* No interstitial lung disease by chest x-ray~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception for 4 weeks before, during, and for 4 weeks after study treatment~* No active pathological condition that would preclude study participation~* No psychological or geographical condition that would preclude study compliance~* No other malignancy within the past 5 years except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior cetuximab~* No prior murine monoclonal antibody therapy (e.g., edrecolomab)~Chemotherapy~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy and recovered~* No concurrent chemotherapy~Radiotherapy~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy and recovered~* Concurrent palliative radiotherapy allowed except to index lesions~Surgery~* At least 4 weeks since prior major surgery and recovered~Other~* No prior EGFR-targeted therapy (e.g., erlotinib or gefitinib)~* More than 30 days since prior experimental therapeutic agents~* More than 4 weeks since prior investigational agents~* No concurrent enrollment in another clinical study~* No other concurrent EGFR-targeted therapy~* No other concurrent non-cytotoxic experimental agents

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete